Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248713 · ClinicalTrials.gov registry record · Early Phase 1
Glucocorticoid Antagonist Treatment for Tobacco Use Disorder
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03248713 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 8 participants.
The verdict
NCT03248713, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this protocol is to examine whether mifepristone, a medication with glucocorticoid receptor antagonist activity, may be a potential treatment for Tobacco Use Disorder (TUD). Mifepristone has already shown promise as a potential treatment for PTSD (1) and alcohol use disorder (AUD) (2), but no previous studies have examined the therapeutic potential of mifepristone for TUD. This will be a double-blind, placebo-controlled study on the effects of a 7-day treatment with 600 mg mifepristone, or placebo, on cognitive function, tobacco withdrawal severity, and smoking behavior.
Interventions
- DRUG Placebo
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2019-05-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248713
The ClinicalTrials.gov registry entry for NCT03248713 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03248713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03248713 about?
NCT03248713 is a clinical study titled "Glucocorticoid Antagonist Treatment for Tobacco Use Disorder". The purpose of this protocol is to examine whether mifepristone, a medication with glucocorticoid receptor antagonist activity, may be a potential treatment for Tobacco Use Disorder (TUD). Mifepristone has already shown promise as a potential treatment for PTSD (1) and alcohol use disorder (AUD) (2)...
What is the current status of trial NCT03248713?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2017-11-29. Estimated completion is 2019-05-20.
What interventions are being tested in trial NCT03248713?
The interventions under investigation include: Placebo (DRUG), Mifepristone (DRUG).
Who is sponsoring clinical trial NCT03248713?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.